ALCIDION GROUP LIMITED (ALC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ALC

ALC - ALCIDION GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.48
Index:

Alcidion Group provides clinical information technology to support clinicians in decision making, ensuring quality of care for patients. The company operates in Australia and the UK. It listed on the ASX in 2011.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.084

05 May
2025

-0.004

OPEN

$0.09

-4.55%

HIGH

$0.09

792,442

LOW

$0.08

TARGET
$0.11 31.0% upside
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . BMT . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL . SLA .
FNARENA'S MARKET CONSENSUS FORECASTS
ALC: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 0.6 0.0 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 410.0 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-0.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx37.1 M
Book Value Per Share xxxxxxxxxxxxxxx6.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-7.1 M
Net Profit Margin xxxxxxxxxxxxxxx-22.71 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-9.51 %
Return on Invested Capital xxxxxxxxxxxxxxx-9.37 %
Return on Assets xxxxxxxxxxxxxxx-7.16 %
Return on Equity xxxxxxxxxxxxxxx-9.51 %
Return on Total Capital xxxxxxxxxxxxxxx-8.45 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-7.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx68 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx12 M
Price To Book Value xxxxxxxxxxxxxxx0.74

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.1 M
Capex % of Sales xxxxxxxxxxxxxxx0.14 %
Cost of Goods Sold xxxxxxxxxxxxxxx39 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx6 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

23/04/2025

1

Buy

$0.11

30.95%

Bell Potter notes Alcidion Group announced a positive March quarter update, slightly ahead of both the broker’s and consensus expectations.

Revenue, including sold and renewal, rose to $40.2m from $37.1m in the previous year and $30.8m in the December quarter. The analyst attributes the $9.4m increase in contracted revenue to the recognition of an $8m–$9m licence fee from the NCIC contract.

Cash balance was $10.2m with no debt, and management upgraded FY25 earnings (EBITDA) guidance to over $3m, in line with the broker's forecast and above consensus.

Target price unchanged at 11c. Buy rating retained.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.02 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.11 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

27/04/2025

1

Buy

$0.13

54.76%

Alcidion Group's 3Q25 update showed contracted revenue rose to $40.2m from $39.5m in February, prompting Canaccord Genuity to slightly upgrade revenue and earnings (EBITDA) estimates for FY25.

The broker notes the company's fixed cost base has opened up the opportunity for operating leverage in FY26 and beyond.

EPS estimates largely unchanged. Buy. No change to 13c target.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.60 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.10 cents.
Access Extra Coverage Research History >

ALC STOCK CHART

FNArena News on ALC

1
Australian Broker Call *Extra* Edition – Apr 27, 2025

Apr 28 2025 - Daily Market Reports
2
Weekly Ratings, Targets, Forecast Changes – 21-03-25

Mar 24 2025 - Weekly Reports
3
Australian Broker Call *Extra* Edition – Mar 05, 2025

Mar 05 2025 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Feb 26, 2025

Feb 26 2025 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Feb 04, 2025

Feb 04 2025 - Daily Market Reports

Latest Healthcare services News

1
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
2
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
3
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
4
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
5
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
6
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
7
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
8
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
9
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
10
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps